RB1 alterations are rare in CDK4/6i-naïve BC patients (0%-3%) but have been detected in up to 11.5% upon progression to CDK4/6i treatment, and are commonly associated with subclonal variants[65,123]. Here, RB1 is linked to breast cancer.